|
4-溴-5-氟-2-甲氧基吡啶
|
B636102-50mg
|
≥97% |
884495-00-5 |
50mg
|
¥ 159.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
4-溴-5-氟-2-甲氧基吡啶
|
B636102-1g
|
≥97% |
884495-00-5 |
1g
|
¥ 1509.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
6-溴-1H-吲哚-4-胺
|
B633674-250mg
|
≥97% |
350800-81-6 |
250mg
|
¥ 225.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
6-溴-1H-吲哚-4-胺
|
B633674-100mg
|
≥97% |
350800-81-6 |
100mg
|
¥ 109.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
荧光增白剂85
|
F352670-2.5kg
|
|
12224-06-5 |
2.5kg
|
¥ 2850.9
|
现货 |
|
0 |
阿拉丁 |
|
Oxford Bio patent anti-Matriptase (anti-Matriptase)
|
Ab209782-100μg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
N/A |
100μg
|
¥ 669.9
|
现货 |
|
0 |
阿拉丁 |
|
Regeneron patent anti-ANGPTL8 (anti-ANGPTL8)
|
Ab209779-100μg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
N/A |
100μg
|
¥ 669.9
|
现货 |
|
0 |
阿拉丁 |
|
Diridavumab (anti-HA)
|
Ab191961-100μg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
1393659-46-5 |
100μg
|
¥ 599.9
|
现货 |
|
0 |
阿拉丁 |
|
Sirtratumab vedotin (anti-SLITRK6)
|
Ab183326-100μg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
1824663-83-3 |
100μg
|
¥ 1509.9
|
现货 |
|
0 |
阿拉丁 |
|
氯化镨
|
P106125-100g
|
≥99.9% metals basis |
10361-79-2 |
100g
|
¥ 1819.9
|
现货 |
|
0 |
阿拉丁 |
|
2-氨基-4-硝基苯酚
|
A766889-500g
|
≥95% |
99-57-0 |
500g
|
¥ 499.9
|
现货 |
|
0 |
阿拉丁 |
|
1-羟基苯并三唑(HOBT)
|
H684271-2.5kg
|
≥99% |
2592-95-2 |
2.5kg
|
¥ 899.9
|
现货 |
|
0 |
阿拉丁 |
|
2-[(乙氧基-硫代甲基)硫代]乙酸
|
A693929-50mg
|
≥98% |
25554-84-1 |
50mg
|
¥ 299.9
|
现货 |
|
0 |
阿拉丁 |
|
2-[(乙氧基-硫代甲基)硫代]乙酸
|
A693929-250mg
|
≥98% |
25554-84-1 |
250mg
|
¥ 899.9
|
现货 |
|
0 |
阿拉丁 |
|
4-羟基甲苯噻嗪
|
H337464-5mg
|
Moligand™, ≥97% |
145356-32-7 |
5mg
|
¥ 5999.9
|
现货 |
|
0 |
阿拉丁 |
|
杀虫脒 盐酸盐
|
C356965-10mg
|
≥98% |
19750-95-9 |
10mg
|
¥ 129.9
|
现货 |
|
0 |
阿拉丁 |
|
2,4,5-三氨基-6-氯嘧啶
|
C190004-1g
|
≥97% |
1194-78-1 |
1g
|
¥ 1523.9
|
现货 |
|
0 |
阿拉丁 |
|
1,4-二羧基苯锆MOF(UiO-66)
|
Z282600-10g
|
粒径:100-500nm,BET比表面1000-2000 m2/g |
1072413-89-8 |
10g
|
¥ 4599.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
5-((Z)-(5-氟-2-氧代吲哚烷-3-亚基)甲基)-2,4-二甲基-1H-吡咯-3-羧酸
|
Z192962-5g
|
≥97% |
356068-93-4 |
5g
|
¥ 789.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
5-((Z)-(5-氟-2-氧代吲哚烷-3-亚基)甲基)-2,4-二甲基-1H-吡咯-3-羧酸
|
Z192962-250mg
|
≥97% |
356068-93-4 |
250mg
|
¥ 89.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
5-((Z)-(5-氟-2-氧代吲哚烷-3-亚基)甲基)-2,4-二甲基-1H-吡咯-3-羧酸
|
Z192962-1g
|
≥97% |
356068-93-4 |
1g
|
¥ 239.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
RIPK1 inhibitor 22b(RIPK1-IN-7)
|
R613198-10mg
|
Moligand™, ≥98% |
2300982-44-7 |
10mg
|
¥ 3469.9
|
现货 |
|
0 |
阿拉丁 |
|
AGS67E (anti-CD37)
|
Ab209859-1mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
N/A |
1mg
|
¥ 3319.9
|
现货 |
|
0 |
阿拉丁 |
|
Tixagevimab (anti-Spike RBD)
|
Ab209842-1mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
2420564-02-7 |
1mg
|
¥ 2599.9
|
现货 |
|
0 |
阿拉丁 |